glutathione therapy for lungs Glutathione-dependent degradation of SMARCA2/4 targeted lung cancer with improved selectivity Metabolic dysregulation in pulmonary fibrosis:

Homocysteine and DNA methylation

TNF- inhibitors, particularly infliximab and adalimumab), and is currently reserved for patients suffering unacceptable side effects, or showing no or insufficient response to first- or second-line treatment, or severe threatening disease manifestation at baseline [1 ,9 ,10,11,50]

Convincing evidence links DI-ALH with immune modulators, such as interferon, infliximab, and imatinib, while there is less evidence regarding statins, adalimumab, and diclofenac [196]

In addition, through various experimental studies, it was shown that ROS may trigger cardiac ectopic activity (25,26), because they affect (prolong) the action potential duration, causing early but also delayed post-depolarization and thus, the activity of aberrant fascicles